Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could be worse.
Outstanding Shares
625,196,572
02/26/2021
The other indexes hanging in there way better and my oils well, they're killing it so it's not likely a full-blown correction coming or everything would be getting slammed in unison across the board.
$SNDL Strategic Investment in Edibles Adds Value to Sundial Growers The Indiva stake only enhances the bull thesis for SNDL stock as the cannabis edibles category emerges By Louis Navellier - InvestorPlace Research Staff, Editor, Growth Investor 2-22-21 https://investorplace.com/2021/02/strategic-investment-in-edibles-adds-value-to-sndl-stock/
$WCEXF // $PUMP.cse - cannabis play and holding company very low price. Making revenue from partially owned subsidiaries. the DD is worth checking out. Linked company, Pineapple Express Delivery, has increasing revenues month over month since last February and contracts/agreements with Canopy and Shopper's drug mart.
as a Canadian a nice low priced spec play for TFSA as well.....
has some awareness but a cursory look at the chart volume seems to indicate there has not been an overly aggressive preloading of shares by anyone prior to this being 'discovered'.
investors hub forum:
https://investorshub.advfn.com/World-Class-Extractions-Inc-WCEXF-39092/
Regards,
Draego
That was quick!! 67 to 70!!
High Tide Opens 70th Nationwide Cannabis Store in Calgary
BY Canada NewsWire
02/10/2021
CALGARY, AB, Feb. 10, 2021 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (CSE: HITI) , an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories and cannabis lifestyle products, announced today that the Canna Cabana retail store located at Unit #130 11130 11 St. NE, in Calgary's Country Hills neighborhood, has begun selling recreational cannabis products for adult use. This opening represents High Tide's 70th retail location across Canada selling recreational cannabis products and consumption accessories.
High Tide Opens New Canna Cabana Store in Calgary's Country Hills Neighbourhood (CNW Group/High Tide Inc.)
"The new store is part of our strategic plan to build scale and drive revenue growth by selectively opening new locations in neighborhoods that aren't over-saturated with existing cannabis retail options," said Raj Grover, President and Chief Executive Officer of High Tide. "As with all stores operating under the High Tide umbrella, this new location will follow our exclusive one-stop-shop approach that allows consumers to purchase all of their cannabis and accessory needs under one roof," added Mr. Grover.
The new Country Hills store continues to expand High Tide's strong foothold in southern Alberta, one of Canada's fastest-growing population centers.
About High Tide Inc. ( HITIF )
High Tide is a retail-focused cannabis company enhanced by the manufacturing and distribution of consumption accessories. The Company is the largest Canadian retailer of recreational cannabis as measured by revenue, with 70 current locations spanning Ontario, Alberta, Manitoba and Saskatchewan. High Tide's retail segment features the Canna Cabana, KushBar, Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis banners, with additional locations under development across the country. High Tide has been serving consumers for over a decade through its numerous consumption accessory businesses including e-commerce platforms Grasscity.com and CBDcity.com, and its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide's strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value. Key industry investors in High Tide include Aphria Inc. and Aurora Cannabis Inc.
FOR REVIEW
Q4 2018 Highlights:
Revenue of $19,147, up 223% compared to the same period in 2017.
November 9, 2020
Aurora Cannabis Announces Fiscal First Quarter 2021 Results
#1 Canadian Medical Position by Cannabis Net Revenue & Strong International Medical Growth
Cannabis Net Revenue of $67.8 million, Adjusted Gross Margin of 48%, or 52% Excluding Nordic 1 Ramp Up Costs
Achieved Targeted SG&A During Q1 2021
EDMONTON, AB, Nov. 9, 2020 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced its financial and operational results for the first quarter of fiscal 2021 ended September 30, 2020.
First Quarter 2021 Highlights
(Unless otherwise stated, comparisons are made between fiscal Q1 2021 and Q4 2020 results and are in Canadian dollars)
Q1 2021 total and cannabis net revenue1 was $67.8 million, a slight increase from the $67.5 million of cannabis net revenue1 in the prior quarter.
Adjusted gross margin before fair value adjustments on cannabis net revenue1 remained strong at 48%, versus 50% in Q4 2020. Excluding $2.6 million of ramp up costs at Aurora Nordic 1, the Company's Q1 2021 adjusted gross margin before fair value adjustments on cannabis net revenue1 was 52%.
Adjusted EBITDA loss was $57.9 million in Q1 2021, which includes restructuring payments such as contract and employee termination costs of $47.4 million. Excluding these impacts, the Company's Adjusted EBITDA loss, as defined under the term credit facility, is $10.5 million. Aurora was in full compliance with its September 30, 2020 term debt covenants. As a reminder, the Company's goal is to achieve positive Adjusted EBITDA in Q2 2021.
Cash balance at November 6, 2020 was approximately $250 million.
Consumer cannabis:
Consumer cannabis net revenue1 was $34.3 million, a 3% decrease from the prior quarter. Of note, Aurora's consumer cannabis extract net revenue increased by $3.6 million as compared to the prior quarter, driven by Aurora's focus on high-growth extract segments such as vapes, edibles and concentrates, and a $1.1 million increase in U.S. CBD.
Adjusted gross margin before fair value adjustments on consumer cannabis net revenue1 was 38% in Q1 2021 versus 35% in the prior quarter, primarily driven by sales mix shifting toward higher margin derivative products
Medical cannabis:
Medical cannabis net revenue1 was $33.5 million, a 4% increase from the prior quarter. The increase was primarily attributable to a strong performance in the international medical business, which grew 41% quarter over quarter, and from consistent performance in Aurora's leading Canadian medical operation.
Adjusted gross margin before fair value adjustments on medical cannabis net revenue1 was 59% in Q1 2021 versus 67% in the prior quarter. Excluding $2.6 million of ramp-up costs at Aurora Nordic 1, Q1 2021 adjusted gross margin before fair value adjustments on medical cannabis was 67%.
Selling, General and Administrative ("SG&A") and Adjusted EBITDA:
SG&A, including Research and Development ("R&D"), was $46.9 million in Q1 2021, down $19.6 million from the prior quarter as a result of the Company's Business Transformation Plan. Included in SG&A is $4.1 million of costs related to restructuring charges, and severance and benefit costs associated with the Business Transformation Plan. Excluding these impacts, Q1 SG&A and R&D was $42.8 million.
Adjusted EBITDA1 in Q1 2021 was a loss of $57.9 million, compared to the prior quarter Adjusted EBITDA loss of $29.6 million when excluding R&D and other restructuring costs. The Q1 increased loss is primarily attributable to the legal settlement and contract termination fees and costs associated to ongoing severance and benefits associated with the business transformation plan. Excluding these impacts, Adjusted EBITDA loss decreased by $19.1 million, or 64%, to $10.5 million, the third sequential quarter of significantly improved Adjusted EBITDA.
Additional Financial Information:
Capital Expenditures ("CapEx") were approximately $13.2 million in Q1 2021, a decline from the $16.4 million reported in Q4 2020.
Aurora continues to execute its announced plan for reducing production and complexity through the closure of 5 cultivation facilities, with three facilities now fully closed. Supporting the Company's drive to align its production footprint to market and geographic demand, Aurora has also recently received flower and oil sales licensing at its EU GMP certified Aurora Nordic 1 facility, located in Odense, Denmark, which is expected to serve European and international medical markets.
Hello Alex,
FYI
I know you guys have your hands full. I just wanted to mention that I started loading up on a stock at $0.15
I have seen it move, methodically, to $0.20, $0.25, $0.30, $0.35 ...
Just wanted to give you guys a heads up, in case you are interested.
)))))) $MJNA )))))))
Initiated in 2014
Opening green is HUGE!!
4.6 + 0.2 (4.55%)
Cannabix Technologies Inc. (BLOZF)
Profit-taking part 3
Part one 30 minutes after open day before yesterday
Part two 30 minutes after open yesterday
Part three 30 minutes after open today
IMO
We should be done with the majority of the "day trader/flipper" profit-taking. (Wrong)
Good to go to add right here. (A loss of 8 cents. Not terrible)
Mark words at $1.07 (Words marked and ... a fail)
Current $0.99
LOD $0.9267
Mark my words .. hee, hee
LOY from today on, rest of the year $0.9267
I think that is an easy call.
All of my profit wiped out last 3 days.
Basis $0.98 I am holding ... for now.
Yes, it`s volatility, up to 4,80 and stayed a bit lower. The overall average is a bit higher then open bid; 4,30.
We will see what happens this week with the stock price. My guess is they will have some news next week, by then it has been a bit more established.
Outstanding Shares
3,534,810
01/12/2021
The following appears to be a boatload of "hot air."
OTC DISCLOSURE & NEWS SERVICE
Lexaria Announces Effective Date for Reverse Stock SplitPress Release | 01/08/2021
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECHPress Release | 12/22/2020
Lexaria Closes Sale of Non-Pharmaceutical THC-Related AssetsPress Release | 12/10/2020
Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor ConferencesPress Release | 12/07/2020
Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral DrugsPress Release | 12/01/2020
Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85MPress Release | 11/19/2020
Lexaria Bioscience Advances 2021 Strategic InitiativesPress Release | 11/05/2020
Lexaria Bioscience Extends Warrant TermPress Release | 10/26/2020
Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than ExpectedPress Release | 10/22/2020
Lexaria Bioscience Granted First European Patent for DehydraTECH TechnologyPress Release | 10/21/2020
Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral DrugsPress Release | 09/29/2020
Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD PowdersPress Release | 09/23/2020
Lexaria Bioscience Continues to Grow its Patent PortfolioPress Release | 09/22/2020
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners CorporationPress Release | 09/16/2020
DGAP-News: Lexaria Bioscience Corp.: Lexaria Bioscience announces R&D agreement with British American TobaccoPress Release | 09/01/2020
Lexaria Bioscience Announces R&D Agreement With British American TobaccoPress Release | 08/31/2020
Lexaria Bioscience to Present at the LD 500 Virtual ConferencePress Release | 08/20/2020
Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure ReductionPress Release | 07/28/2020
Lexaria BioScience Files Application with Senior U.S. Stock Exchange for UplistingPress Release | 07/21/2020
DGAP-News: Altria and Lexaria Conclude Phase I Research and Development ProgramPress Release | 07/16/2020
Thx John, it could have been worse as well as better. Giving the circumstances now, it`s good enough is my view. The first 2 days on Nasdaq and small steps up.
Considering it might take some time, to get a broader audience being aware of the "new" stock, I`m looking forward to the announced coming big news.
It will show if it`s a temporary climb up, or we actually is growing the trader/investor base. Volume has been over expectation so far, giving no news has been presented yet in the connection with up listing on Nasdaq.
New ticker; LEXX - Lexaria Bioscience Corp.
I could only dream of a 1 for 30 split. Congrats.
LXRP Increased CBD orders! - big name customer is? Lexaria may become a true winner and a money maker as well.
What kind of customer are they talking about?
Lexaria Bioscience has broadened its COVID-19 drug exploration program, and they believe its DehydraTech has the potential to significantly increase bio-availability, safety, and efficacy for many oral antiviral medications. This development is expected to make oral antiviral drugs work more effectively for better therapeutic outcomes and at lower doses than are otherwise necessary in order to minimize unwanted side effects. In turn, this may also make the oral route of administration a viable alternative to injection. One such drug of note is the antiviral remdesivir. This is a game changing and disruptive technological development.
Yesterday, LXRP did a one for 30 reverse split in order to qualify for the NASDAQ, and is anticipated to list with a new symbol LEXX today. Opening price is expected to be $7.50 per share once fully approved and listed.
I checked this morning and as of 5:00am central it comes up as LXRPD on OTC, but on TD Ameritrade it comes up as LEXX and is listed as NASDAQ. In conjunction with this up-listing, the company intends to raise 1.8 million dollars.
Listing on a major U.S. exchange should not be overlooked because NASDAQ is backed by serious money, and media is not so shy about suggesting major exchange listed stocks as opposed to OTC listed companies. Chris Bunka (CEO of Lexaria) has stated numerous times he needed this listing to garner the attention of the big pharmaceutical companies, big tobacco, and big beverage companies he intends to partner with. Potentially, this up-listing could be just the beginning, and no one knows where it might end up.
If fully listed on NASDAQ today, Lexaria has accomplished a major feat that many OTC companies only talk about or merely dream of doing. Today, a new reality may dawn.
Cannabix Technologies Granted U.S. Patent - Cannabis Drug Detection Device
For immediate release. Vancouver, British Columbia, January 12, 2021: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company. The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ?9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.
Cannabix Technologies Granted U.S. Patent - Cannabis Drug Detection Device
For immediate release. Vancouver, British Columbia, January 12, 2021: Cannabix Technologies Inc.(CSE: BLO, OTC PINK: BLOZF) (the “Company”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the United States Patent and Trademark Office (USPTO) has granted patent No. 14/689434 entitled, “Cannabis Drug Detection Device” to the Company.
The Company and its patent attorneys have been pursuing this patent application since its filing in 2014. Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ?9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment.
“The intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2014. Considering the field of breath detection of drugs is in its infancy, this patent is a useful step in our IP protection strategy” said Dr. Raj Attariwala.
In light of the granting of U.S. patent 14/689434, the Company undertaken a strategic review of its existing patent applications and will re-align its portfolio by canceling its second license agreement with the University of Florida (UF) in relation to patent application 16/082,220. The Company will continue with its original license agreement with UF in relation to patent 8,237,118.
As a requirement under the license agreement between the Company and Cannabix Breathalyzer Inc. (a separate entity) entered into on June 5th, 2014, Company will issue 5 million common shares to Cannabix Breathalyzer Inc. as a final milestone payment, triggered by the grant of patent 14/689434 by the USPTO.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing portable tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples.
In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous and for personal use testing.
More Good News From HEXO
HEXO Corp Announces Downward Revision to its Proposed Share Consolidation Ratio
December 07, 2020
Source: HEXO Corp.
OTTAWA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NYSE:HEXO) announces that it has made an amendment (the “Amendment”) to its notice of meeting dated October 28, 2020 (the “Notice of Meeting”) and its management information circular dated October 28, 2020 (the “Circular”) in respect of its annual and special meeting of shareholders scheduled to be held on December 11, 2020 (the “Meeting”).
The Notice of Meeting and the Information Circular provided that, at the Meeting, shareholders of the Company (“Shareholders”) would be asked to consider, and if deemed advisable, pass a special resolution authorizing and approving a consolidation of the outstanding common shares of the Company (“Common Shares”) on the basis of eight (8) old Common Shares for one (1) new Common Share, all as more particularly described in the Circular (the “Original Consolidation Ratio”). The purpose of the consolidation is to increase the Company's common share price to regain compliance with the US$1.00 minimum share price continued listing standard of the New York Stock Exchange (“NYSE”).
The Company believes the Original Consolidation Ratio should be revised downward in light of the recent increase in the trading price of the Common Shares and in order to maintain a liquid share float and reflect the Company’s confidence that it can execute on its growth strategy. It is therefore changing the ratio for the proposed consolidation of the Common Shares from the Original Consolidation Ratio to a ratio of four (4) old Common Shares for one (1) new Common Share (the “New Consolidation Ratio”). Accordingly, all references in the Notice of Meeting and the Information Circular to the Original Consolidation Ratio are amended to refer to the New Consolidation Ratio.
“We believe that our solid financial position and the execution of our growth strategy is not yet reflected in our market valuation. We are number one in Canada in key categories such as beverages and have continued to gain sales momentum in critical markets including Ontario and Alberta. We are currently sitting fourth in recreational cannabis sales in Canada, with the gap between us and third place narrowing, while the gap between us and those behind us has widened”, said Sébastien St-Louis, HEXO CEO and co-founder.
“Given the necessity to regain compliance with the US$1.00 minimum share price continued listing standard, we are in the position of having to seek approval for the consolidation to avoid de-listing from the NYSE. It is important to maintain liquidity for our investors, and we’ve made the decision to consolidate our shares. This change in the consolidation ratio to 4:1, from the previously announced 8:1, is indicative of the confidence we have in our ability to execute going forward, as we look beyond positive EBITDA to earnings on a per share basis.”
ANYBODY AWAKE ON THIS BOARD BESIDES MIMADMAN AND MYSELF??
HIGH TIDE (HITIF)
CANN.ca $HERTF Heritage Cannabis to Acquire Premium 5 Ltd.
by @businesswire on 23 Dec 2020, 06:09
Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that it has entered into a definitive agreement (the “Agreement”) to acquire all of the issued and outstanding securities of Premium 5 Ltd. (“Premium 5”), a Canada-based recreational and medical cannabis company that creates high-quality full spectrum concentrates under the brand Premium 5.
Premium 5 is a leader in developing and launching products, proven by successfully introducing one of the first hydrocarbon products in the Canadian recreational and medical markets as well as becoming the first to launch live resin vapes. It currently offers two sought-after brands in eight provinces across Canada, as well as Shelter Market and Shoppers Drug Mart.
Premium 5 offers a wide range of high-quality products that encompass premium, core, and value priced brands in both the recreational and medical markets, creating a leading portfolio of products in the Cannabis 2.0 space focused on derivative concentrates. It is best known for its namesake brand – Premium 5 which is first in the premium hydrocarbon and solventless concentrates category, as well as the newly launched RAD value brand which is first in the value hydrocarbon concentrate, flower and distillate vape categories.
Currently, Premium 5 has entered eight of the 13 provincial and territorial recreational markets including the three largest, British Columbia, Alberta, and Ontario and have strong product listings on the two leading medical platforms; Shelter Market (13 listed products) and Shoppers Drug Mart’s online cannabis platform (11 listed products). In total, Premium 5 has 66 SKU offerings and a strong product development pipeline with a focus on innovation and quality.
High demand for Premium 5 products has resulted in provincial purchase orders nearing $10 million since launching sales in June 2020 and growing each month to an annualized run-rate of approximately $20 million. The launch has been met with strong consumer acceptance as highlighted by sustained re-order rates across Canada including over $2 million in the month of December.
For Heritage, this transaction delivers on several key critical strategic objectives:
Immediate coast to coast sales
Strong margins with an emphasis to drive additional synergies
Increased focus on execution and speed-to-market
Strong product development pipeline
Under the terms of the Agreement, Premium 5 will receive initial consideration of CDN$21.0 million of common shares of Heritage, plus additional Heritage common shares to compensate the shareholders of Premium 5 for the Net Working Capital of Premium 5 as of the closing date.. The Agreement additionally includes a series of revenue growth and gross margin milestones over the next 24 months to earn potential consideration of up to an additional CDN$20.0 million payable in common shares of Heritage.
“The acquisition of Premium 5 brings a strong team with proven brands and products to Heritage’s platform. The combination of Premium 5’s portfolio and our successful line-up of sought-after products creates an impressive catalog of products for both the provincial boards and consumers across Canada,” stated Clint Sharples, CEO of Heritage. “The Premium 5 approach of offering high quality products aligns well with our strategy, and also caters to multiple consumer categories and price points. As a result of these product listings, Heritage will have significant product choice for consumers across the country. This is a significant step in growing our platform both domestically and internationally.”
As part of the transaction, Premium 5 CEO David Schwede will become the President of Heritage’s recreational cannabis division. Prior to his role as CEO of Premium 5, he was Senior Manager of Product Development and Project Management for one of Canada’s largest revenue producing cannabis companies. With a history as CEO of tech start-ups, he is an entrepreneur who has successfully operated and scaled multiple businesses that have won several start-up awards with his most recent being one of Forbes start-ups to watch for 2019.
“We have built a strong brand in a core part of the market that continues to grow. Our focus is to combine our innovation and execution with the Heritage infrastructure to leverage our combined team and further expand our reach both domestically and abroad. We look forward to building on past successes as part of the Heritage family,” said David Schwede.
The transaction is subject to customary closing conditions and is expected to be completed before the end of January 2021. Hillcrest Merchant Partners is acting as the exclusive financial advisor to Premium 5.
About Heritage Cannabis Holdings Corp.
Heritage is a vertically integrated cannabis provider that currently has two Health Canada approved licensed producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licenses, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and a Medical Services Division which is focused on cannabis based medical solutions. In the U.S., Heritage operates under Opticann Inc., a Colorado based oral and topical cannabinoid company with the rights to exclusively sell CBD and CBG products made with the patented VESIsorb® drug delivery system for optimized absorption and stability. As the parent company, Heritage is focused on providing the resources for its subsidiaries to advance their products or services to compete both domestically and internationally.
About Premium 5 Ltd.
Premium 5 products offer a feeling that only the terpenes from a high terpene full spectrum concentrate can give, to encourage customers to find their feeling. Premium 5 is dedicated to creating high-quality full spectrum concentrates, selling a premium high THC experience, and providing a healthier more discrete way to medicate and consume. Products offered under the Premium 5 brand are crafted from indoor grown, fresh-frozen, whole bud that has been carefully selected for optimal cannabinoid and terpene profiles to offer customers only the most exceptional quality. Premium 5 prides themselves in being consumer-driven to delight their partners, their consumers, and their communities.
ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.
“Clint Sharples”
Clint Sharples
CEO
The Canadian Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information contained herein may include, but is not limited to, assumptions related to cash flow and capital resources, and expectations related to the supply and manufacturing agreements, the intended expansion of the Company, and partnerships and Joint Venture Partnerships.
By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements.
An investment in securities of the Company is speculative and subject to several risks including, without limitation, the risks discussed under the heading "Risks and Uncertainties" in the Company's annual management discussion and analysis for the year ended October 31, 2019 and dated February 28, 2020, as well as the interim management discussion and analysis for the quarter ended July 31, 2020 and dated September 29, 2020. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.
In connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this notice.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005257/en/
Highlights for the Second Quarter Ended August 31, 2020
THR entered into a cannabis supply agreement with the province of British Columbia through the British Columbia Liquor Distribution Branch as well as completing initial sales into the province. This is the 5th province in Canada to carry the Company’s CALIBER branded indoor-grown dried flower products.
The Company secured a private loan of $855,000 from Infusion Biosciences Inc., a related party of the Company. The Loan carries an interest rate of 15% per annum accruing and compounding monthly, payable on maturity on or before October 24, 2020.
The Company completed a non-brokered private placement of 1,500,000 units of the Company at a price of $0.07 per Equity Unit to raise gross proceeds of $105,000. Each Equity Unit consists of one Common Share and one Warrant, with each Warrant entitling the holder to acquire one Warrant Share at an exercise price equal to $0.08 for a period of two years from date of issuance.
The Company completed a settlement of outstanding current debt of the Company in the amount of $180,000 with an arm’s length creditor. In settlement of the Debt, the Company has issued 1,800,000 Common Shares (the “Settlement Shares”) at a price of $0.10 per Settlement Share.
Subsequent Events
The Company’s wholly-owned subsidiary, Toronto Herbal Remedies Inc., (“THR”), a licensed producer and processor under the Cannabis Act, has received its cannabis extract sales license from Health Canada (the “Sales License”). THR is now authorized to manufacture and sell Cannabis 2.0 products directly to provincial distributors and other authorized Canadian retail supply channels.
THR’s ability to sell Cannabis 2.0 products allows it to utilize its licensed APP technology and offer the Company’s strain specific cannabis extracts, edible and beverage products in Canada through its existing provincial sales relationships.
The Company amended maturity date of its previously issued convertible debentures from October 24, 2020 to April 24, 2021 and reduced the conversion price from $0.105 to $0.06 per share.
The Company and Infusion Biosciences Inc. (“Infusion”) extended the maturity dates of both the $1 million private loan issued by Infusion to the Company on January 28, 2020 and the $855,000 private loan issued by Infusion to the Company on August 27, 2020 by six months to April 24, 2021.
The Company settled an aggregate of $182,340 of payroll indebtedness owed to certain current and former employees for past services rendered through the issuance of 2,604,867 common shares at a deemed issuance price of $0.07 per share.
The Company settled an aggregate of approximately $69,300 of indebtedness owed to one arms-length creditor for past services rendered through the issuance of 1,386,000 common shares at a deemed issuance price of $0.05 per share.
Outstanding Shares
305,423,415
12/11/2020
August 31, 2020
Revenue $344,049
May 31, 2020
Revenue $25,875
CANN.c $HERTF by @businesswire on 14 Dec 2020, 04:02
Heritage Cannabis Announces Pura Vida and Purefarma Products Now Available in Alberta
Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), is pleased to announce that it has received an inaugural order from Alberta Gaming, Liquor & Cannabis (“AGLC”) to sell Heritage products in the province.
Alberta Customers will soon be able to purchase all seven vape cartridge products offered by Heritage including Pura Vida CBD 4:1 Honey Oil, and Indica, Sativa and Hybrid Honey Oil vape cartridges, as well as Purefarma Moon, Sun and CBD Earth vape cartridges. Heritage launched both Pura Vida and Purefarma vape cartridges in September 2020 and the response by customers has been tremendous in the three provinces in which they are available – British Columbia, Manitoba and Saskatchewan - as well as across Canada on the Patient Choice platform at www.patient-choice.com.
Heritage CEO Clint Sharples said, “This initial order from Alberta is our largest order for our vape products that we have seen since launching our products this year. Heritage’s award winning, full spectrum products are intended to provide the highest value for the price – something we expect all consumers, including Alberta, will appreciate. The province has ordered all seven of our vape products, which will provide the Alberta market with a multitude of choices, and we expect to see a similar response as in other provinces where products sell out quickly.”
Heritage’s products have a strong customer following supported by multiple industry awards. Pura Vida THC and CBD extract products have received first place awards in the 2016 Emerald Cannabis Cup. In the 2017 High Times Cannabis Cup, they also placed first in the Best Vaporizer and Sativa Concentrate categories and took second place for both Indica and Hybrid Concentrates. In the 2018 Emerald Cannabis Cup, Pura Vida placed first and third in the concentrate and flower categories.
Follow Heritage’s Purefarma and Pura Vida brands on Instagram and Facebook for more information.
About Heritage Cannabis Holdings Corp.
Heritage Cannabis is a vertically integrated cannabis provider that currently has two Health Canada approved licensed producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licenses, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and a Medical Services Division, which is focused on cannabis based medical solutions. In the U.S., Heritage operates under Opticann Inc., a Colorado based oral and topical cannabinoid company with the rights to exclusively sell CBD and CBG products made with the patented VESIsorb® drug delivery system for optimized absorption and stability. As the parent company, Heritage is focused on providing the resources for its subsidiaries to advance their products or services to compete both domestically and internationally.
ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.
“Clint Sharples”
Clint Sharples
CEO
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005225/en/
$MJNA Medical Marijuana, Inc., nice entry
$AXIM AXIM Biotechnologies, Inc. is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company's NeuCovix is the rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. It is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was founded in 2010 and is headquartered in San Diego, California.
https://finance.yahoo.com/quote/AXIM?p=AXIM&.tsrc=fin-srch
American Green, Inc. $ERBB
$ALYI "Hemp Super Battery in development"
Aurora Cannabis Inc. $ACB Top Institutional Holders
Holder Shares Date Reported % Out Value
ETF Managers Group, LLC 4,618,063 Sep 29, 2020 3.27% 21,473,992
Vanguard Group, Inc. (The) 2,970,656 Sep 29, 2020 2.10% 13,813,550
Morgan Stanley 1,123,802 Sep 29, 2020 0.80% 5,225,679
JP Morgan Chase & Company 785,141 Sep 29, 2020 0.56% 3,650,905
Susquehanna International Group, LLP 654,028 Sep 29, 2020 0.46% 3,041,230
Shaw D.E. & Co., Inc. 635,766 Sep 29, 2020 0.45% 2,956,311
Citadel Advisors LLC 522,569 Sep 29, 2020 0.37% 2,429,945
Bank of America Corporation 451,275 Sep 29, 2020 0.32% 2,098,428
Renaissance Technologies, LLC 447,378 Sep 29, 2020 0.32% 2,080,307
Bank of Montreal/Can/ 422,748 Sep 29, 2020 0.30% 1,965,778
Top Mutual Fund Holders
Holder Shares Date Reported % Out Value
ETF Managers Tr-EFTMG Alternative Harvest ETF 4,618,063 Sep 29, 2020 3.27% 21,473,992
Vanguard International Stock Index-Total Intl Stock Indx 1,703,529 Jul 30, 2020 1.21% 17,358,960
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 682,344 Sep 29, 2020 0.48% 3,172,899
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 296,644 Jul 30, 2020 0.21% 3,022,802
Global X Fds-The Global X Cannabis ETF 155,370 Oct 30, 2020 0.11% 629,248
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 150,892 Aug 30, 2020 0.11% 1,478,741
College Retirement Equities Fund-Stock Account 125,336 Jun 29, 2020 0.09% 1,556,673
Spinnaker ETF Tr-Cannabis ETF 96,197 Aug 30, 2020 0.07% 942,730
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF 42,914 Oct 30, 2020 0.03% 173,801
iShares Core MSCI International Developed Markets ETF 37,992 Oct 30, 2020 0.03% 153,867
https://finance.yahoo.com/quote/ACB/holders?p=ACB
$APHA Aphria Cannabis Top Institutional Holders
Holder Shares Date Reported % Out Value
Vanguard Group, Inc. (The) 7,499,273 Sep 29, 2020 2.51% 33,221,779
ETF Managers Group, LLC 4,947,746 Sep 29, 2020 1.66% 21,918,514
Susquehanna International Group, LLP 2,295,246 Sep 29, 2020 0.77% 10,167,939
Peconic Partners, LLC 2,015,515 Sep 29, 2020 0.68% 8,928,731
Bank of Montreal/Can/ 1,026,840 Sep 29, 2020 0.34% 4,548,901
Morgan Stanley 932,540 Sep 29, 2020 0.31% 4,131,152
TD Asset Management, Inc 922,233 Sep 29, 2020 0.31% 4,085,492
Public Sector Pension Investment Board 818,253 Sep 29, 2020 0.27% 3,624,860
AdvisorShares Investments, LLC 735,685 Sep 29, 2020 0.25% 3,259,084
Swiss National Bank 579,300 Sep 29, 2020 0.19% 2,566,299
Top Mutual Fund Holders
Holder Shares Date Reported % Out Value
ETF Managers Tr-EFTMG Alternative Harvest ETF 4,947,746 Sep 29, 2020 1.66% 21,918,514
Vanguard International Stock Index-Total Intl Stock Indx 3,800,716 Jul 30, 2020 1.27% 18,148,418
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 1,723,413 Sep 29, 2020 0.58% 7,634,719
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index 744,923 Jul 30, 2020 0.25% 3,557,007
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF 735,685 Sep 29, 2020 0.25% 3,259,084
College Retirement Equities Fund-Stock Account 455,139 Jun 29, 2020 0.15% 1,952,546
Schwab Strategic Tr-Schwab International Small Cap Equity ETF 379,342 Aug 30, 2020 0.13% 1,847,395
Global X Fds-The Global X Cannabis ETF 331,567 Oct 30, 2020 0.11% 1,492,051
Spinnaker ETF Tr-Cannabis ETF 329,542 Aug 30, 2020 0.11% 1,604,869
TIAA-CREF Funds-Quant International Small Cap Equity Fund 273,000 Jul 30, 2020 0.09% 1,303,575
https://finance.yahoo.com/quote/APHA/holders?p=APHA
LXRP, Yesterdays Interview with CEO, Mr Chris Bunka
Lexaria Bioscience proves technology works in enhancing oral delivery of antiviral drugs
Bombed out name, revs still decent looking to do 30M in revs in the coming year,HK and Ont expansions going on, enough to keep an eye on...imho...cheers...hsb
What in the world are you doing following Wildflower?
SUN.ca $WLDFF Wildflower Brands closes $434,600 financing
2020-12-03 12:49 ET - News Release
Mr. Krystian Wetulani reports
WILDFLOWER BRANDS CLOSES FINANCING AND PROVIDES CORPORATE UPDATE
Wildflower Brands Inc. has closed the previously announced financing for aggregate gross proceeds of $434,600.
Each unit consists of one common share at 15 cents and one share purchase warrant exercisable at 30 cents for a period of 2 years. No finders' fees were paid. Directors of the Company participated for $150,000 of the said financing.
The proceeds of the financing are being used for the Rubicon Organics launch. The Company has already shipped a $150,000 filling machine to the Rubicon facility in Delta, BC to manufacture its topical line of products. Packaging and ingredients are being purchased to service the 840 stores across Western Canada and Ontario that Rubicon fulfills. Launch is targeted for February 2021.
Wildflower Wellness products have achieved shelf space at Lane Crawford stores in Hong Kong in time for the Holiday season which meets the projected timelines. Worth noting is that the Hong Kong retail luxury sales account for 5-10% of global sales and penetrating the Asian market is a major milestone for the Company's growth.
The build-out of City Cannabis's flagship Toronto store is well underway bringing City Cannabis's unique and unmatched cannabis retail experience to the Ontario market for the first time. The location of the Toronto store is the first to service both the luxury retail market and the financial district. Other locations are in various stages of approval.
"The above-mentioned update is being accomplished through existing cashflow as well as proceeds from this financing," says Wildflower's CEO William MacLean. "This truly speaks to the resilience of our team and the strength of the business we've built. We look forward to the significant value these developments will create for our shareholders."
Further to the Company's news release dated October 29, 2020, the Company's principal regulator, the British Columbia Securities Commission (BCSC) granted a management cease trade order (the "MCTO") on October 29, 2020, under National Policy 12-203 Management Cease Trade Orders ("NP 12-203").
Pursuant to the MCTO, the Chief Executive Officer, Chief Financial Officer, and Chief Development Officer may not trade in securities of the Company until such time as the Company files its annual audited financial statements for the year ended June 30, 2020, management's discussion and analysis and related certifications (collectively, the "Required Documents") and the Executive Director of the BCSC revokes the MCTO. The MCTO does not affect the ability of shareholders to trade their securities.
The Company's Board of Directors and management confirm that they are working expeditiously to file the Required Documents and confirm that since the Company's news release dated October 29, 2020, there is no other material information respecting the Company's affairs that has not been generally disclosed.
Until the Required Documents have been filed, the Company intends to continue to satisfy the provisions of the alternative information guidelines specified in NP 12-203 by issuing bi-weekly default status reports in the form of further press releases for so long as the Company remains in default of a specified requirement.
ABOUT WILDFLOWER BRANDS INC.
Wildflower Brands is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products. All of our brands work in synergy, toward becoming a global wellness leader.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved
Penny, I'll take a look, but the last thing I need is another name. I have a ton of good names in the MJ space. Too many.
Low volume can be a problem IF you want to exit.
Outstanding Shares
82,556,403
11/13/2020
Good!!
Vibe is a vertically integrated cannabis company whose mission is to become a dominant California cannabis retailer and multi-state operator. The Company delivers exceptional retail experiences with its Vibe by California brand and ethos, premier cultivation product, and high-efficiency delivery and distribution. The Company's management team brings expertise in retail, cannabis cultivation, and mergers and acquisitions to support its U.S. expansion through accretive acquisitions and organic growth.
I found one that im not in yet that looks interesting. They are Canadian that are now headquartered in California. They have pretty nice revenues and just had a merger. They are operating out of California and Oregon and I believe they plan on expanding to other states. They have website info and you can find the company on twitter @VibeBioscience $VBSCF low volume and looks pretty overlooked at this point.
VFF.to interview with the Cannibus Hour Team @Benzinga.com interesting insight into the shenanigans required to address all of HC concerns in the legal weed vs black market space...starts at 42:00 mins mark
SUN.c $WLDFF Could be a nice inverted Head and Shoulders setting up here on the weekly? http://schrts.co/smATBeVR 0
If all goes well, this will be a monster for me. I have 60,000 shares. If I pump that up to 100,000, every one penny move equals a gain of $1,000
I am looking for next stop at $0.25
With 60,000 shares that would equate to $6,000
With 100,000 shares, $10,000
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |